EA015366B1 - Производное триазола в качестве ингибитора hsp90 - Google Patents

Производное триазола в качестве ингибитора hsp90 Download PDF

Info

Publication number
EA015366B1
EA015366B1 EA200900913A EA200900913A EA015366B1 EA 015366 B1 EA015366 B1 EA 015366B1 EA 200900913 A EA200900913 A EA 200900913A EA 200900913 A EA200900913 A EA 200900913A EA 015366 B1 EA015366 B1 EA 015366B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer
diseases
hydroxy
methyl
triazol
Prior art date
Application number
EA200900913A
Other languages
English (en)
Russian (ru)
Other versions
EA200900913A1 (ru
Inventor
Ханс-Михаэль Эггенвайлер
Михаэль Вольф
Ханс-Петер Бухшталлер
Кристиан Зирренберг
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA200900913A1 publication Critical patent/EA200900913A1/ru
Publication of EA015366B1 publication Critical patent/EA015366B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
EA200900913A 2007-01-18 2007-12-11 Производное триазола в качестве ингибитора hsp90 EA015366B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102007002715A DE102007002715A1 (de) 2007-01-18 2007-01-18 Triazolderivat
PCT/EP2007/010775 WO2008086857A1 (de) 2007-01-18 2007-12-11 Triazolderivat als hsp 90 inhibitor

Publications (2)

Publication Number Publication Date
EA200900913A1 EA200900913A1 (ru) 2009-12-30
EA015366B1 true EA015366B1 (ru) 2011-06-30

Family

ID=39345628

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900913A EA015366B1 (ru) 2007-01-18 2007-12-11 Производное триазола в качестве ингибитора hsp90

Country Status (22)

Country Link
US (1) US8816070B2 (cg-RX-API-DMAC10.html)
EP (1) EP2102175B1 (cg-RX-API-DMAC10.html)
JP (1) JP5266253B2 (cg-RX-API-DMAC10.html)
KR (1) KR20090101381A (cg-RX-API-DMAC10.html)
CN (1) CN101583605B (cg-RX-API-DMAC10.html)
AR (1) AR064951A1 (cg-RX-API-DMAC10.html)
AU (1) AU2007344512B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0720956A2 (cg-RX-API-DMAC10.html)
CA (1) CA2675737C (cg-RX-API-DMAC10.html)
CL (1) CL2008000134A1 (cg-RX-API-DMAC10.html)
DE (1) DE102007002715A1 (cg-RX-API-DMAC10.html)
EA (1) EA015366B1 (cg-RX-API-DMAC10.html)
EC (1) ECSP099586A (cg-RX-API-DMAC10.html)
ES (1) ES2455504T3 (cg-RX-API-DMAC10.html)
MX (1) MX2009007479A (cg-RX-API-DMAC10.html)
MY (1) MY151452A (cg-RX-API-DMAC10.html)
NZ (1) NZ579069A (cg-RX-API-DMAC10.html)
PE (1) PE20090051A1 (cg-RX-API-DMAC10.html)
TW (1) TW200838502A (cg-RX-API-DMAC10.html)
UA (1) UA98320C2 (cg-RX-API-DMAC10.html)
WO (1) WO2008086857A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200905700B (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742133B2 (en) * 2007-08-13 2014-06-03 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
RS53716B1 (sr) * 2009-10-19 2015-04-30 Synta Pharmaceuticals Corp. Kombinovana terapija kancera sa hsp90 inhibitornim jedinjenjima
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
DE102010024338A1 (de) 2010-06-18 2011-12-22 Merck Patent Gmbh Verfahren zur Herstellung von 5-[4-(2-Methyl-phenyl)-3-hydroxy-4H-[1,2,4]triazol-5-yl]-2,4-dihydroxy-methyl-butyl-benzamid
HRP20150462T1 (hr) * 2010-10-01 2015-07-17 Taisho Pharmaceutical Co., Ltd Derivat 1,2,4-triazolona
CN103391777A (zh) * 2011-02-02 2013-11-13 普林斯顿大学理事会 作为病毒产生调节剂的去乙酰化酶调节剂
WO2013067162A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN106478531B (zh) * 2015-08-25 2019-06-28 南京华威医药科技集团有限公司 2-(5-溴-4-(4-环丙基萘-1-基)-4h-1,2,4-三唑-3-基硫基)乙酸中间体
MX2025007723A (es) * 2018-05-14 2025-08-01 Reata Pharmaceuticals Inc Biarilamidas con grupos de azucar modificados para el tratamiento de enfermedades asociadas con la trayectoria de la proteina de choque de calor
CN115006395B (zh) * 2022-04-29 2023-03-14 佛山病原微生物研究院 一种xl888在制备用于抗腺病毒感染的药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087077A2 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Hsp90 hemmende triazolderivate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968921A (en) 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration
WO1999051223A1 (en) 1998-04-03 1999-10-14 University Of Pittsburgh Of The Commonwealth System Of Higher Education Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke
AU776652B2 (en) 1999-03-12 2004-09-16 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Method of inhibiting a chaperone protein
WO2001072779A1 (en) 2000-03-24 2001-10-04 Duke University Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto
US6887853B2 (en) 2000-06-29 2005-05-03 The Trustees Of Boston University Use of geldanamycin and related compounds for treatment of fibrogenic disorders
EP1322325A4 (en) 2000-07-20 2004-09-15 Merck & Co Inc INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
US6946456B2 (en) 2000-07-28 2005-09-20 Sloan-Kettering Institute For Cancer Research Methods for treating cell proliferative disorders and viral infections
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2003041643A2 (en) 2001-11-09 2003-05-22 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
JP4399265B2 (ja) 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
US20050054625A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors
US20050026893A1 (en) 2003-05-30 2005-02-03 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with immunosuppressants
US20050020557A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020556A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with platinum coordination complexes
US20050054589A1 (en) 2003-05-30 2005-03-10 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antibiotics
US20050020534A1 (en) 2003-05-30 2005-01-27 Kosan Biosciences, Inc. Method for treating diseases using HSP90-inhibiting agents in combination with antimetabolites
ES2594874T3 (es) * 2004-11-18 2016-12-23 Synta Pharmaceuticals Corp. Compuestos de triazol que modulan la actividad de HSP90

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006087077A2 (de) * 2005-02-17 2006-08-24 Merck Patent Gmbh Hsp90 hemmende triazolderivate

Also Published As

Publication number Publication date
CL2008000134A1 (es) 2008-05-16
ECSP099586A (es) 2009-09-29
TW200838502A (en) 2008-10-01
EA200900913A1 (ru) 2009-12-30
EP2102175B1 (de) 2014-01-22
MY151452A (en) 2014-05-30
DE102007002715A1 (de) 2008-07-24
CA2675737A1 (en) 2008-07-24
JP5266253B2 (ja) 2013-08-21
US20100113542A1 (en) 2010-05-06
NZ579069A (en) 2011-09-30
CA2675737C (en) 2015-03-24
AR064951A1 (es) 2009-05-06
MX2009007479A (es) 2009-08-13
PE20090051A1 (es) 2009-01-26
BRPI0720956A2 (pt) 2014-03-18
AU2007344512B2 (en) 2012-11-01
AU2007344512A1 (en) 2008-07-24
JP2010516639A (ja) 2010-05-20
KR20090101381A (ko) 2009-09-25
ES2455504T3 (es) 2014-04-15
WO2008086857A1 (de) 2008-07-24
CN101583605B (zh) 2013-06-19
US8816070B2 (en) 2014-08-26
CN101583605A (zh) 2009-11-18
ZA200905700B (en) 2010-05-26
EP2102175A1 (de) 2009-09-23
UA98320C2 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
JP5266253B2 (ja) Hsp90阻害剤としてのトリアゾール誘導体
ES2375114T3 (es) Derivados de indazolamida.
ES2394513T3 (es) Derivados triazol inhibidores de HSP90
CA2652394C (en) Triazole derivatives ii
ES2410537T3 (es) 1,5-Difenilpirazoles II como inhibidores de HSP90
ES2494920T3 (es) 3-(2-hidroxifenil)-pirazoles y su utilización como moduladores de la HSP90
CN101180278B (zh) 2-氨基-4-苯基喹唑啉衍生物以及其作为hsp90调节剂的用途
EP2181092B1 (de) 1,3-dihydro-isoindolderivate
EP1857446B1 (en) Derivatives of 3-(2,4-dihydroxyphenyl)-1,2,4-triazole useful in the treatment of cancer
CN102245596A (zh) 喹唑啉酰胺衍生物
JP5841059B2 (ja) キナゾリン誘導体
WO2008089436A2 (en) Crystalline forms of histone deacetylase inhibitors
MX2007014720A (es) Tienopiridinas.
JP5953306B2 (ja) フェニルキナゾリン誘導体
HK1138588A (en) Triazole derivative as an hsp 90 inhibitor
HK1146935A (zh) 1,3-二氢异吲哚衍生物
HK1164293A (zh) 喹唑啉酰胺衍生物
HK1119690B (en) 2-amino-4-phenylquinazoline derivates and their use as hsp90 modulators
HK1114839B (en) Hsp90-inhibiting triazole derivatives
HK1131979A (en) 1,5-diphenylpyrazoles ii as hsp90 inhibitors
HK1145176A (en) Quinazolinamide derivatives

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU